CY1120976T1 - Δις ειδικα αντισωματα igg σαν παραγοντες ενεργοποιησης τ κυτταρων - Google Patents
Δις ειδικα αντισωματα igg σαν παραγοντες ενεργοποιησης τ κυτταρωνInfo
- Publication number
- CY1120976T1 CY1120976T1 CY20181101099T CY181101099T CY1120976T1 CY 1120976 T1 CY1120976 T1 CY 1120976T1 CY 20181101099 T CY20181101099 T CY 20181101099T CY 181101099 T CY181101099 T CY 181101099T CY 1120976 T1 CY1120976 T1 CY 1120976T1
- Authority
- CY
- Cyprus
- Prior art keywords
- igg antibodies
- specific igg
- cell activating
- activating factors
- typ
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει δις ειδικά ανθρώπινα αντισώματα IgG, όπου ένας βραχίονας του αντισώματος δεσμεύει ένα επίτοπο πάνω σε ανοσοποιητικά δραστικά κύτταρα, ενώ ο άλλος βραχίονας στοχεύει CLEC12A ή ένα λειτουργικό ισοδύναμο αυτού. Παρέχονται επίσης φαρμακευτικές χρήσεις αυτών των αντισωμάτων έναντι κακοηθειών όπως MDS, CML ή AML.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261706543P | 2012-09-27 | 2012-09-27 | |
US201361834915P | 2013-06-14 | 2013-06-14 | |
PCT/NL2013/050693 WO2014051433A1 (en) | 2012-09-27 | 2013-09-27 | BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1120976T1 true CY1120976T1 (el) | 2020-05-29 |
Family
ID=49382559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20181101099T CY1120976T1 (el) | 2012-09-27 | 2018-10-25 | Δις ειδικα αντισωματα igg σαν παραγοντες ενεργοποιησης τ κυτταρων |
Country Status (27)
Country | Link |
---|---|
US (2) | US10358492B2 (el) |
EP (2) | EP3470431A1 (el) |
JP (2) | JP6471095B2 (el) |
KR (1) | KR102390177B1 (el) |
CN (2) | CN110066338B (el) |
AU (2) | AU2013324527B9 (el) |
BR (1) | BR112015006824A2 (el) |
CA (1) | CA2889681C (el) |
CY (1) | CY1120976T1 (el) |
DK (1) | DK2900694T3 (el) |
EA (1) | EA201590640A1 (el) |
ES (1) | ES2692951T3 (el) |
HK (1) | HK1211966A1 (el) |
HR (1) | HRP20181717T1 (el) |
HU (1) | HUE042040T2 (el) |
IL (1) | IL237945B (el) |
LT (1) | LT2900694T (el) |
MX (1) | MX2015003885A (el) |
NZ (1) | NZ630563A (el) |
PL (1) | PL2900694T3 (el) |
PT (1) | PT2900694T (el) |
RS (1) | RS57910B1 (el) |
SG (2) | SG11201502451QA (el) |
SI (1) | SI2900694T1 (el) |
TR (1) | TR201815768T4 (el) |
WO (1) | WO2014051433A1 (el) |
ZA (1) | ZA201502835B (el) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
CA2872136C (en) | 2002-07-18 | 2017-06-20 | Merus B.V. | Recombinant production of mixtures of antibodies |
TWI671403B (zh) | 2005-03-31 | 2019-09-11 | 中外製藥股份有限公司 | 控制組裝之多肽的製造方法 |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
PE20081216A1 (es) | 2006-09-01 | 2008-09-04 | Therapeutic Human Polyclonals Inc | Expresion mejorada de la inmunoglobulina humana o humanizada en animales transgenicos no humanos |
MX369784B (es) | 2007-09-26 | 2019-11-21 | Chugai Pharmaceutical Co Ltd | Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr). |
RU2663123C2 (ru) | 2010-11-30 | 2018-08-01 | Чугаи Сейяку Кабусики Кайся | Индуцирующий цитотоксичность терапевтический агент |
ES2743399T3 (es) | 2012-04-20 | 2020-02-19 | Merus Nv | Métodos y medios para la producción de moléculas heterodiméricas similares a Ig |
EP3470431A1 (en) * | 2012-09-27 | 2019-04-17 | Merus N.V. | Bispecific igg antibodies as t cell engagers |
TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
EP2968552B1 (en) | 2013-03-14 | 2020-03-11 | The Scripps Research Institute | Targeting agent antibody conjugates and uses thereof |
US10072093B2 (en) * | 2013-07-04 | 2018-09-11 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Fusion protein to target and treat acute myeloid leukemia cells |
RU2758952C1 (ru) | 2013-09-27 | 2021-11-03 | Чугаи Сейяку Кабусики Кайся | Способ получения полипептидного гетеромультимера |
WO2015130172A1 (en) | 2014-02-28 | 2015-09-03 | Merus B.V. | Antibodies that bind egfr and erbb3 |
US11279770B2 (en) | 2014-02-28 | 2022-03-22 | Merus N.V. | Antibody that binds ErbB-2 and ErbB-3 |
TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
AU2015292811B2 (en) | 2014-07-21 | 2019-12-19 | Novartis Ag | Treatment of cancer using a CLL-1 chimeric antigen receptor |
EP3191520B1 (en) | 2014-09-12 | 2020-01-01 | Genentech, Inc. | Anti-cll-1 antibodies and immunoconjugates |
MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
PL3221359T3 (pl) | 2014-11-17 | 2020-11-16 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia nowotworów przy użyciu dwuswoistego przeciwciała CD3XCD20 |
KR20170087486A (ko) * | 2014-11-20 | 2017-07-28 | 에프. 호프만-라 로슈 아게 | 일반 경쇄 및 이의 사용 방법 |
ES2835823T3 (es) | 2014-11-20 | 2021-06-23 | Hoffmann La Roche | Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T para CD3 y para el receptor de folato 1 (FolR1) y antagonistas de la unión al eje de PD-1 |
AU2016219170B2 (en) * | 2015-02-13 | 2021-09-09 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CTLA4 |
CN107921121B (zh) * | 2015-03-04 | 2022-02-08 | 索伦托药业有限公司 | 结合cd47的抗体治疗剂 |
AU2016242866B2 (en) | 2015-03-30 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to FC gamma receptors |
WO2016159213A1 (ja) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
TW201718647A (zh) | 2015-06-16 | 2017-06-01 | 建南德克公司 | 抗-cll-1抗體及使用方法 |
DK3115376T3 (en) * | 2015-07-10 | 2018-11-26 | Merus Nv | HUMANT CD3 BINDING ANTIBODY |
CN108290951B (zh) * | 2015-09-23 | 2022-04-01 | 瑞泽恩制药公司 | 优化抗cd3双特异性抗体和其用途 |
CN108602888B (zh) | 2015-10-23 | 2022-10-04 | 美勒斯公司 | 抑制癌症生长的结合分子 |
SG11201802698XA (en) * | 2015-10-29 | 2018-05-30 | Hoffmann La Roche | Transgenic rabbit with common light chain |
EP3851457A1 (en) | 2016-01-21 | 2021-07-21 | Novartis AG | Multispecific molecules targeting cll-1 |
CA3016424A1 (en) | 2016-03-14 | 2017-09-21 | Chugai Seiyaku Kabushiki Kaisha | Cell injury inducing therapeutic drug for use in cancer therapy |
EP3464365A1 (en) * | 2016-06-01 | 2019-04-10 | Xencor, Inc. | Bispecific antibodies that bind cd123 and cd3 |
US20190307799A1 (en) | 2016-09-23 | 2019-10-10 | The Regents Of The University Of Michigan | Engineered lymphocytes |
AU2018219887A1 (en) | 2017-02-08 | 2019-08-22 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
KR20190120782A (ko) | 2017-02-20 | 2019-10-24 | 드래곤플라이 쎄라퓨틱스, 인크. | Her2, nkg2d 및 cd16에 결합하는 단백질 |
WO2018152530A1 (en) * | 2017-02-20 | 2018-08-23 | Adimab, Llc | Proteins binding gd2, nkg2d and cd16 |
AU2018246873B2 (en) | 2017-03-31 | 2021-05-06 | Merus N.V. | ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene |
CN111278460A (zh) * | 2017-05-23 | 2020-06-12 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
MX2019014000A (es) * | 2017-05-23 | 2020-07-29 | Dragonfly Therapeutics Inc | Una proteína que se une a nkg2d, cd16 y un antígeno asociado a un tumor. |
CA3068929A1 (en) * | 2017-07-06 | 2019-01-10 | Merus N.V. | Binding molecules that modulate a biological activity expressed by a cell |
KR20200037250A (ko) | 2017-07-06 | 2020-04-08 | 메뤼스 엔.페. | 세포에 의해 발현되는 생물학적 활성을 조절하는 항체 |
EP3649155A1 (en) * | 2017-07-06 | 2020-05-13 | Merus N.V. | Bispecific anti pd1-anti tim3 antibodies |
SG11202001050PA (en) | 2017-08-09 | 2020-03-30 | Merus Nv | Antibodies that bind egfr and cmet |
WO2019055677A1 (en) * | 2017-09-14 | 2019-03-21 | Dragonfly Therapeutics, Inc. | NKG2D, CD16, AND LIQUID-LIKE MOLECULE-1-LIKE PROTEINS (CLL-1) |
TW201930351A (zh) | 2017-10-06 | 2019-08-01 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
US11161911B2 (en) | 2017-10-23 | 2021-11-02 | Go Therapeutics, Inc. | Anti-glyco-MUC1 antibodies and their uses |
WO2019108065A1 (en) | 2017-12-01 | 2019-06-06 | Merus N.V. | Use of bispecific antibody and il-15 for combination therapy |
AU2019218136A1 (en) | 2018-02-08 | 2020-08-13 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
TWI804572B (zh) | 2018-02-09 | 2023-06-11 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
AU2019243665B2 (en) * | 2018-03-30 | 2023-06-01 | Merus N.V. | Multivalent antibody |
KR20210020932A (ko) | 2018-06-13 | 2021-02-24 | 노파르티스 아게 | Bcma 키메라 항원 수용체 및 이의 용도 |
WO2019246379A1 (en) * | 2018-06-22 | 2019-12-26 | Cugene Inc. | Novel interleukin-15 (1l-15) fusion proteins and uses thereof |
CA3110513A1 (en) | 2018-08-31 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies |
JP7453971B2 (ja) * | 2018-10-19 | 2024-03-21 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | Nkエンゲージャー分子およびその使用方法 |
US20210340274A1 (en) * | 2018-10-25 | 2021-11-04 | The Medical College Of Wisconsin, Inc. | Targeting CLPTMIL for Treatment and Prevention of Cancer |
JP2022521036A (ja) * | 2018-12-20 | 2022-04-05 | メルス ナムローゼ フェンノートシャップ | CLEC12AxCD3二重特異性抗体及び疾患の治療方法 |
CN113439089A (zh) | 2018-12-31 | 2021-09-24 | 美勒斯公司 | 截短的多价多元体 |
TW202039578A (zh) | 2019-03-29 | 2020-11-01 | 荷蘭商美勒斯公司 | Cd3結合分子 |
TW202102544A (zh) | 2019-04-04 | 2021-01-16 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
MX2021013417A (es) * | 2019-05-04 | 2021-12-10 | Inhibrx Inc | Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos. |
WO2021006199A1 (ja) | 2019-07-05 | 2021-01-14 | 小野薬品工業株式会社 | Pd-1/cd3二重特異性タンパク質による血液がん治療 |
TW202118790A (zh) | 2019-07-30 | 2021-05-16 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
WO2021025140A1 (ja) | 2019-08-08 | 2021-02-11 | 小野薬品工業株式会社 | 二重特異性タンパク質 |
AU2020368354A1 (en) * | 2019-10-17 | 2022-05-12 | Regents Of The University Of Minnesota | CLEC12A antibody fragment sequences and methods |
CN116199780A (zh) | 2019-12-24 | 2023-06-02 | 美勒斯公司 | TGF-β-RII结合蛋白质 |
US20230279121A1 (en) | 2020-08-05 | 2023-09-07 | Dragonfly Therapeutics, Inc. | Antibodies targeting egfr and use thereof |
US20230111279A1 (en) * | 2021-04-26 | 2023-04-13 | Millennium Pharmaceuticals, Inc. | Anti-clec12a antibodies and uses thereof |
KR20240035504A (ko) * | 2021-07-20 | 2024-03-15 | 에이비엘바이오 주식회사 | 항-cll-1 항체 및 이의 용도 |
US20230220106A1 (en) | 2021-12-08 | 2023-07-13 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
GB202214132D0 (en) * | 2022-09-27 | 2022-11-09 | Coding Bio Ltd | CLL1 binding molecules |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4801687A (en) | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
FI884924A (fi) | 1987-10-28 | 1989-04-29 | Oncogen | Humanimmuglobulin som producerats med hybrid-dna-teknik. |
US5151504A (en) | 1989-11-17 | 1992-09-29 | E. R. Squibb & Sons, Inc. | Method for purification of monoclonal antibodies |
GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
JP3502093B2 (ja) | 1991-07-15 | 2004-03-02 | ザ・ウエルカム・ファウンデーション・リミテッド | 抗体の製造 |
US5457035A (en) * | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
ES2246069T3 (es) * | 1997-05-02 | 2006-02-01 | Genentech, Inc. | Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos. |
SI1533380T1 (sl) | 1999-04-15 | 2010-03-31 | Crucell Holland Bv | Proizvajanje rekombinantnega proteina v človeški celici ki obsega vsaj en protein E adenovirusa |
BRPI0210771B8 (pt) | 2001-07-04 | 2021-05-25 | Chromagenics Bv | construção de dna recombinante, método para a produção de um produto de gene em uma célula, e, uso de uma sequência de dna |
US20050130224A1 (en) | 2002-05-31 | 2005-06-16 | Celestar Lexico- Sciences, Inc. | Interaction predicting device |
CA2872136C (en) * | 2002-07-18 | 2017-06-20 | Merus B.V. | Recombinant production of mixtures of antibodies |
JP2006517188A (ja) * | 2002-12-02 | 2006-07-20 | アブジェニックス・インコーポレーテッド | ホスホリパーゼa2に対する抗体及びその使用 |
CA2512647C (en) | 2003-01-07 | 2013-10-08 | Symphogen A/S | Method for manufacturing recombinant polyclonal proteins |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
CA2526284C (en) * | 2003-06-25 | 2014-11-18 | Crucell Holland B.V. | Binding molecules for the treatment of myeloid cell malignancies |
MXPA06014075A (es) * | 2004-06-03 | 2007-03-15 | Novimmune Sa | Anticuerpos anti-cd3 y metodos de uso de los mismos. |
CN1984931B (zh) | 2004-06-03 | 2012-11-28 | 诺维莫尼公司 | 抗-cd3抗体及其使用方法 |
SE527196C2 (sv) | 2004-07-08 | 2006-01-17 | Chemel Ab | SIRE genomflödesdetektor |
AU2005282700A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
US20060171929A1 (en) | 2005-01-31 | 2006-08-03 | The University Of Washington | Regulation of dendritic cell functions by the DCAL-2 receptor |
CA2602663A1 (en) | 2005-03-31 | 2006-10-05 | Xencor, Inc. | Fc variants with optimized properties |
JP2008537941A (ja) * | 2005-03-31 | 2008-10-02 | ゼンコー・インコーポレイテッド | 最適化特性を有するFc変異体 |
TWI671403B (zh) | 2005-03-31 | 2019-09-11 | 中外製藥股份有限公司 | 控制組裝之多肽的製造方法 |
GB2429517B (en) | 2005-07-15 | 2010-10-06 | Viridian Concepts Ltd | Solar collector devices |
WO2007047901A2 (en) | 2005-10-18 | 2007-04-26 | Lacy Kolo | Credit fraud prevention systems and methods |
WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
US8290739B2 (en) | 2006-10-20 | 2012-10-16 | Amfit, Inc. | Method for determining relative mobility of regions of an object |
AU2008234248C1 (en) | 2007-03-29 | 2015-01-22 | Genmab A/S | Bispecific antibodies and methods for production thereof |
JP2010536341A (ja) | 2007-08-15 | 2010-12-02 | アムニクス, インコーポレイテッド | 生物学的に活性なポリペプチドの特性を改変するための組成物および方法 |
WO2009051974A1 (en) * | 2007-10-17 | 2009-04-23 | Nuvelo, Inc. | Antibodes to cll-1 |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
SI2235064T1 (sl) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov |
JP5530367B2 (ja) | 2008-02-05 | 2014-06-25 | ザイムワークス,インコーポレイテッド | 分子動力学を使用してタンパク質またはその他のバイオポリマー中の相関残基を決定するための方法 |
AU2009263082C1 (en) | 2008-06-27 | 2018-11-01 | Merus N.V. | Antibody producing non-human mammals |
JP2012515540A (ja) | 2009-01-26 | 2012-07-12 | ゲンマブ エー/エス | 抗体混合物を産生するための方法 |
TWI461211B (zh) | 2009-03-20 | 2014-11-21 | Genentech Inc | 抗-her抗體 |
EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
CN102471378B (zh) * | 2009-06-26 | 2014-04-02 | 瑞泽恩制药公司 | 容易地分离的具有天然免疫球蛋白形式的双特异性抗体 |
WO2011028952A1 (en) * | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
SI3095871T1 (sl) | 2010-02-08 | 2019-06-28 | Regeneron Pharmaceuticals, Inc. | Miš z navadno lahko verigo |
EP2569337A1 (en) | 2010-05-14 | 2013-03-20 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
CA2808154A1 (en) * | 2010-08-13 | 2012-02-16 | Medimmmune Limited | Monomeric polypeptides comprising variant fc regions and methods of use |
ES2537207T3 (es) | 2010-08-16 | 2015-06-03 | Novimmune S.A. | Métodos para la generación de anticuerpos multiespecíficos y multivalentes |
CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
SG10201602371VA (en) | 2011-03-25 | 2016-04-28 | Glenmark Pharmaceuticals Sa | Hetero-dimeric immunoglobulins |
CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
ES2743399T3 (es) | 2012-04-20 | 2020-02-19 | Merus Nv | Métodos y medios para la producción de moléculas heterodiméricas similares a Ig |
EP3470431A1 (en) | 2012-09-27 | 2019-04-17 | Merus N.V. | Bispecific igg antibodies as t cell engagers |
DK3115376T3 (en) | 2015-07-10 | 2018-11-26 | Merus Nv | HUMANT CD3 BINDING ANTIBODY |
-
2013
- 2013-09-27 EP EP18192737.7A patent/EP3470431A1/en active Pending
- 2013-09-27 AU AU2013324527A patent/AU2013324527B9/en active Active
- 2013-09-27 SI SI201331229T patent/SI2900694T1/sl unknown
- 2013-09-27 HU HUE13777349A patent/HUE042040T2/hu unknown
- 2013-09-27 DK DK13777349.5T patent/DK2900694T3/en active
- 2013-09-27 US US14/040,023 patent/US10358492B2/en active Active
- 2013-09-27 SG SG11201502451QA patent/SG11201502451QA/en unknown
- 2013-09-27 CN CN201811462337.9A patent/CN110066338B/zh active Active
- 2013-09-27 PL PL13777349T patent/PL2900694T3/pl unknown
- 2013-09-27 PT PT13777349T patent/PT2900694T/pt unknown
- 2013-09-27 LT LTEP13777349.5T patent/LT2900694T/lt unknown
- 2013-09-27 EA EA201590640A patent/EA201590640A1/ru unknown
- 2013-09-27 WO PCT/NL2013/050693 patent/WO2014051433A1/en active Application Filing
- 2013-09-27 EP EP13777349.5A patent/EP2900694B1/en active Active
- 2013-09-27 JP JP2015534421A patent/JP6471095B2/ja active Active
- 2013-09-27 CA CA2889681A patent/CA2889681C/en active Active
- 2013-09-27 MX MX2015003885A patent/MX2015003885A/es unknown
- 2013-09-27 CN CN201380061615.9A patent/CN105051066B/zh active Active
- 2013-09-27 RS RS20181217A patent/RS57910B1/sr unknown
- 2013-09-27 SG SG10201705787VA patent/SG10201705787VA/en unknown
- 2013-09-27 NZ NZ630563A patent/NZ630563A/en unknown
- 2013-09-27 TR TR2018/15768T patent/TR201815768T4/tr unknown
- 2013-09-27 KR KR1020157010993A patent/KR102390177B1/ko active IP Right Grant
- 2013-09-27 BR BR112015006824A patent/BR112015006824A2/pt not_active Application Discontinuation
- 2013-09-27 ES ES13777349.5T patent/ES2692951T3/es active Active
-
2015
- 2015-03-25 IL IL237945A patent/IL237945B/en unknown
- 2015-04-24 ZA ZA2015/02835A patent/ZA201502835B/en unknown
-
2016
- 2016-01-05 HK HK16100035.9A patent/HK1211966A1/xx unknown
-
2018
- 2018-06-12 AU AU2018204173A patent/AU2018204173B2/en active Active
- 2018-10-19 HR HRP20181717TT patent/HRP20181717T1/hr unknown
- 2018-10-25 CY CY20181101099T patent/CY1120976T1/el unknown
- 2018-11-01 JP JP2018206388A patent/JP2019068803A/ja active Pending
-
2019
- 2019-04-19 US US16/389,356 patent/US20190352393A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120976T1 (el) | Δις ειδικα αντισωματα igg σαν παραγοντες ενεργοποιησης τ κυτταρων | |
CY1119287T1 (el) | Συζευγματα αντισωματων πυρρολοβενζοδιαζεπινης-αντι-her2 | |
CY1120637T1 (el) | Πολυπεπτιδικα αντισωματα που ανταγωνιζονται cd40 | |
BR112019014986A8 (pt) | Anticorpo que alveja bcma e uso do mesmo | |
AU2018258045A1 (en) | Chimeric antibody/T-cell receptor constructs and uses thereof | |
MX2022014125A (es) | Anticuerpos y conjugados de los mismos. | |
BR112015010436A2 (pt) | Anticorpos anti-notch3 e conjugados anticorpo-fármaco | |
BR112019008854A2 (pt) | ligantes contendo peptídeo para conjugados de anticorpo-fármaco | |
WO2016070089A3 (en) | Anti-cs1 antibodies and antibody drug conjugates | |
CR20140585A (es) | Proteinas de union a antigeno st2 | |
EA201590171A1 (ru) | ИММУНОКОНЪЮГАТЫ, СОДЕРЖАЩИЕ АНТИТЕЛА К CD79b | |
CU20150128A7 (es) | Conjugados fármaco-anticuerpo | |
EA201991715A1 (ru) | Композиции, содержащие антитело к pdl1 | |
EA201390933A1 (ru) | Антитела против мезотелина и иммуноконъюгаты | |
EA201590174A1 (ru) | Иммуноконъюгаты, содержащие анти-cd22 антитела | |
UY35399A (es) | Conjugados de fármacos con anticuerpos | |
MX2019003214A (es) | Formulaciones de proteina de inmunoglobulina del dominio variable dual estable. | |
NZ703581A (en) | Anti-cd70 antibody drug conjugates | |
EA201591750A1 (ru) | Антитела против b7-h4 и иммуноконъюгаты | |
EA201400875A1 (ru) | Антитела к cd47 и способы их применения | |
EA201491811A1 (ru) | АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ | |
EA201390850A1 (ru) | Противоопухолевые комбинации, содержащие специфически распознающие cd38 антитела и бортезомиб | |
BR112017001588A2 (pt) | conjugados de anticorpo/fármaco anti-cdh6 | |
EA201590173A1 (ru) | Иммуноконъюгаты, содержащие антитела к cd22 | |
CY1121829T1 (el) | Κατιονικα πολυμερη που εχουν τη βαση τους στο γλυκογονο |